Big Data EEG Analysis for Advanced Personalised Medicine in Depression
Modern medicine has given us countless methods of understanding, measuring and managing such metrics of our health as temperature, weight, body fat percentage, cholesterol, PSA values, etc. A patient’s measured values are easily c...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Debrasa
Deep brain targets for neurostimulation in affective disorde...
187K€
Cerrado
NEUROMODEL
Statistical Modelling for relating multimodal neuroimaging t...
200K€
Cerrado
WhiteBox EEG
Big Data EEG Recording and Analysis platform
71K€
Cerrado
Información proyecto PREDICT
Duración del proyecto: 23 meses
Fecha Inicio: 2019-05-23
Fecha Fin: 2021-04-30
Líder del proyecto
ELMINDA LTD
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
3M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Modern medicine has given us countless methods of understanding, measuring and managing such metrics of our health as temperature, weight, body fat percentage, cholesterol, PSA values, etc. A patient’s measured values are easily compared against well-established normal ranges. And yet a simple, non-invasive method for measuring and quantifying the health of our brains has eluded us. Being unable to accurately measure and compare how a brain functions hinders doctors’ ability to diagnose and treat suspected ailments. It also slows the substantiation of new therapies. And, just as importantly, it prevents each of us from truly understanding and taking ownership of the health of our body’s most important organ. Major Depressive Disorder (MDD) has been identified as the leading and most costly mental disorder, accounting for 33% of the total cost of brain disorders, and equal to 1% of the GDP. Each year, about 7% of the population suffer from MDD in Europe, equivalent to 52.98 million people. The current methods of treatment are prescribed through trial and error with patients rarely receiving the ‘right’ treatment from day one. This reduces response rates and delays remission, which has a heavy impact on the individual’s quality of life. elminda has developed the PREDICT tool which predicts responsiveness to antidepressants and TMS treatment, and thus dramatically reduces time from diagnosis to amelioration of symptoms for MDD patients. PREDICT determines personalised treatments for MDD patients based on validated electroencephalogram and event-related potential brain-related biomarkers. The tool predicts responsiveness to antidepressants and TMS treatment, and thus dramatically reduces time from diagnosis to amelioration of symptoms. This improves response rates, quality of life and results in significant savings for the healthcare systems.